Low protein diet supplemented with ketoanalogues in patients with chronic renal failure: a randomized study to compare two kinds of ketoanalogues tablets
GONG De-hua,XU Bin,ZHU Dong-dong,GAO Chun-juan,LIU Zhi-hong,JI Da-xi
DOI: https://doi.org/10.3969/j.issn.1006-298X.2012.05.004
2012-01-01
Abstract:Objective: By a prospective randomized controlled study, to compare the efficacy of low protein diet supplemented with two kinds of ketoanalogues tablets in treatment of patients with chronic renal failure. Methodology:From May,2010 to Oct,2010,the patients diagnosed as chronic renal failure who regularly visited the outpatient department of Jinling hospital were screened for enrolment. The major inclusion criteria were as following: serum creatinine (SCr) 132～265 μmol/L; stable renal function status without active disease; and primary glomerular disease was supposed to be the primary diagnosis. All patients were recommended to adhere to a diet with protein intake less than 0.6 g/(kg·d) and received the same routine renal protective therapy before being randomly allocated into Keluodi and Ketosteril group supplemented with ketoanalogues tablets Keluodi or Ketosteril, respectively. They were followed at timepoint 0,2,4, and 6th month, for recording of main complains, weight, height and blood and urine tests, as well as body fat and lean weight using bioimpedance analysis method. Results:Each group enrolled 32 patients, with 2 dropouts in Keluodi (KLD) group and 1 dropout in Ketosteril (KT) group. Finally 61 patients were entered into data analysis. There was no difference in baseline values between two groups in age, sex, body mass index, blood hemoglobin,SCr,cystatin C (CysC), endogenous creatinine clearance (CCr), estimated glomerular filtration rate (eGFR), urine proteinexcretion, drugs intake, and diet protein intake (DPI). No obvious side effects were recorded during the follow up period. At the endpoint, compared with baseline, following parameters had significant declined in both group: weight [0 vs 6th month:KLD group (59.0±8.9 vs 57.8±8.4 kg),KT group (61.8±11.7 vs 60.6±11.3 kg),P<0.05],serum urate [0 vs 6th month:KLD group (483±84.1 vs 439.4±80.1 μmol/L),KT group (485±96.1 vs 426±61.2 μmol/L),P<0.01];following parameters had significantly elevated in both group: serum calcium [0 vs 6th month:KLD group (2.3±0.1 vs (2.4±0.1 mmol/L),KT group (2.3±0.2 vs 2.4±0.2 mmol/L),P<0.01], serum IgG [0 vs 6th month:KLD group(13.8±2.6 vs 15.1±3.2 g/L),KT group (14.3±2.9 vs 15.1±3.7 g/L),P<0.05], urine protein excretion (0 vs 6th month:KLD group (0.41±0.33 vs (0.79±0.78 g/24h),KT group (0.61±0.53 vs 0.77±0.59 g/24h),P<0.01]; following parameter had significantly decreased only in KT group but not in KLD group: serum pre-albumin [0 vs 6th month:KT group (376.5±89.5 vs 318.3±77.0 mg/L),P<0.001;KLD group (393±104 vs 349.4±72.0 mg/L),P>0.05]; following parameter had significantly increased only in KLD group but not in KT group: CCr [0 vs 6th month:KLD group (36.5±13.5 vs 40.1±14.5 ml/min),P<0.05,KT group (37.3±17.8 vs 39.5±17.7 ml/min),P>0.05]; other parameters including body lean weight, serum albumin, serum transferrin, lipids, hemoglobin, SCr, CysC, serum phosphorus and eGFR had no significant changes. Conclusion:Low-protein diet supplemented with two kinds of ketoanalogues tablets has no significant different effects in treatment of patients with chronic renal failure, in regarding nutrition status and renal function preservation, as well as side effects.